| Description | LY96 Human Pre-designed siRNA Set A contains three designed siRNAs for LY96 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components LY96 siRNA-1: 5 nmol (HPLC) LY96 siRNA-2: 5 nmol (HPLC) LY96 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 LY96 Human Pre-designed siRNA Set A contains three designed siRNAs for LY96 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components LY96 siRNA-1: 5 nmol (HPLC) LY96 siRNA-2: 5 nmol (HPLC) LY96 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC 50 of 4 µM. IRAK-4 protein kinase inhibitor 2 can be used for the research of inflammatory and immune-related conditions or disordersIn VitroIRAK-4 IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC 50 of 4 µM. IRAK-4 protein kinase inhibitor 2 can be used for the research of inflammatory and immune-related conditions or disordersIn VitroIRAK-4 protein kinase inhibitor 2 (compound 1) also inhibits IRAK-1, with an IC 50 of <10 µM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.IC50& Target:IRAK4 4 µM (IC 50 )... Read More | Lipoprotein Lipase Activator is a cell-permeable benzylphosphonate derivative that selectively induces lipoprotein lipase (LPL) mRNA and protein levels, but does not exhibit PPARα or PPARγ agonistic activities. Lipoprotein Lipase Activator lowers serum lipid levels and plasma triglyceridesLipoprotein Lipase Activator is a cell-permeable benzylphosphonate derivative that selectively induces lipoprotein lipase (LPL) mRNA and protein levels, but does not exhibit PPARα or PPARγ agonistic activities. Lipoprotein Lipase Activator lowers serum lipid levels and plasma triglycerides with concomitant elevation in high-density lipoprotein cholesterol (HDL-C) in animal models. Lipoprotein Lipase Activator also induces fatty acid oxidation related enzymes, lowers free fatty acids (FFA), and minimizes fat accumulation. Also reported to suppress the plasma levels of TNF-a and COX-2 and displays anti-tumor properties... Read More | Purity≥ 92% SDS-PAGEActual molecular weight 15&17kDaFunctionChemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. Augments monocyte anti-tumor activity. Has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like Purity≥ 92% SDS-PAGEActual molecular weight 15&17kDaFunctionChemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. Augments monocyte anti-tumor activity. Has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis... Read More | VEGF permeability factor, also known as Vascular permeability factor (VPF), is a highly specific permeability factor for endothelial growth factor. It can promote the increase of vascular permeability, extracellular matrix degeneration, vascular endothelial cell migration, proliferation and VEGF permeability factor, also known as Vascular permeability factor (VPF), is a highly specific permeability factor for endothelial growth factor. It can promote the increase of vascular permeability, extracellular matrix degeneration, vascular endothelial cell migration, proliferation and angiogenesis. VEGF has also been shown to have chemotaxis on monocytes and osteoblasts.OsrhVEGF is expressed by oryza sativa and purified by protein purification technology... Read More |